Quick Answer
Akebia Therapeutics, Inc. reported Net Income Loss of -$5.35 million for the year ending 2025.
- Akebia Therapeutics, Inc. showed an increase of +92.3% in Net Income Loss from 2024 to 2025.
- This data is from Akebia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2016: -$36.31 million | Q4 2016: -$37.86 million | Q1 2017: -$44.54 million | Q2 2017: -$21.52 million | Q3 2017: -$23.13 million | Q4 2017: $15.52 million | Q1 2018: -$23.42 million | Q2 2018: -$34.07 million | Q3 2018: -$26.05 million | Q4 2018: -$60.05 million | Q1 2019: -$72.42 million | Q2 2019: -$58.17 million | Q3 2019: -$54.59 million | Q4 2019: -$94.48 million | Q1 2020: -$60.75 million | Q2 2020: -$175.75 million | Q3 2020: -$59.96 million | Q4 2020: -$87.00 million | Q1 2021: -$69.58 million | Q2 2021: -$83.04 million | Q3 2021: -$59.54 million | Q1 2022: -$63.51 million | Q2 2022: $29.45 million | Q3 2022: -$54.10 million | Q1 2023: -$26.88 million | Q2 2023: -$11.17 million | Q3 2023: -$14.49 million | Q1 2024: -$17.99 million | Q2 2024: -$8.58 million | Q3 2024: -$20.04 million | Q1 2025: $6.11 million | Q2 2025: $247.0 thousand | Q3 2025: $540.0 thousand.
- Over the full 14 years of available data (2012 to 2025), Akebia Therapeutics, Inc.'s Net Income Loss has grown by 34.8%.
- Historical annual values: Fiscal year 2025: -$5.35 million | Fiscal year 2024: -$69.41 million | Fiscal year 2023: -$51.93 million | Fiscal year 2022: -$94.23 million | Fiscal year 2021: -$282.84 million | Fiscal year 2020: -$383.46 million | Fiscal year 2019: -$279.66 million | Fiscal year 2018: -$143.59 million | Fiscal year 2017: -$73.67 million | Fiscal year 2016: -$135.75 million | Fiscal year 2015: -$60.72 million | Fiscal year 2014: -$37.03 million | Fiscal year 2013: -$13.17 million | Fiscal year 2012: -$8.20 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: